Literature DB >> 16271053

The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells.

Abedelnasser Abulrob1, Hein Sprong, Paul Van Bergen en Henegouwen, Danica Stanimirovic.   

Abstract

Antibodies against receptors that undergo transcytosis across the blood-brain barrier (BBB) have been used as vectors to target drugs or therapeutic peptides into the brain. We have recently discovered a novel single domain antibody, FC5, which transmigrates across human cerebral endothelial cells in vitro and the BBB in vivo. The purpose of this study was to characterize mechanisms of FC5 endocytosis and transcytosis across the BBB and its putative receptor on human brain endothelial cells. The transport of FC5 across human brain endothelial cells was polarized, charge independent and temperature dependent, suggesting a receptor-mediated process. FC5 taken up by human brain endothelial cells co-localized with clathrin but not with caveolin-1 by immunochemistry and was detected in clathrin-enriched subcellular fractions by western blot. The transendothelial migration of FC5 was reduced by inhibitors of clathrin-mediated endocytosis, K+ depletion and chlorpromazine, but was insensitive to caveolae inhibitors, filipin, nystatin or methyl-beta-cyclodextrin. Following internalization, FC5 was targeted to early endosomes, bypassed late endosomes/lysosomes and remained intact after transcytosis. The transcytosis process was inhibited by agents that affect actin cytoskeleton or intracellular signaling through PI3-kinase. Pretreatment of human brain endothelial cells with wheatgerm agglutinin, sialic acid, alpha(2,3)-neuraminidase or Maackia amurensis agglutinin that recognizes alpha(2,3)-, but not with Sambucus nigra agglutinin that recognizes alpha(2,6) sialylgalactosyl residues, significantly reduced FC5 transcytosis. FC5 failed to recognize brain endothelial cells-derived lipids, suggesting that it binds luminal alpha(2,3)-sialoglycoprotein receptor which triggers clathrin-mediated endocytosis. This putative receptor may be a new target for developing brain-targeting drug delivery vectors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16271053     DOI: 10.1111/j.1471-4159.2005.03463.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  55 in total

Review 1.  Strategies to improve drug delivery across the blood-brain barrier.

Authors:  Albertus G de Boer; Pieter J Gaillard
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 2.  Blood-brain barrier transport of therapeutics via receptor-mediation.

Authors:  Angela R Jones; Eric V Shusta
Journal:  Pharm Res       Date:  2007-07-10       Impact factor: 4.200

3.  Using microdialysis to analyse the passage of monovalent nanobodies through the blood-brain barrier.

Authors:  G Caljon; V Caveliers; T Lahoutte; B Stijlemans; G H Ghassabeh; J Van Den Abbeele; I Smolders; P De Baetselier; Y Michotte; S Muyldermans; S Magez; R Clinckers
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 4.  Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.

Authors:  Catherine J Hutchings; Markus Koglin; William C Olson; Fiona H Marshall
Journal:  Nat Rev Drug Discov       Date:  2017-07-14       Impact factor: 84.694

Review 5.  Developing therapeutic antibodies for neurodegenerative disease.

Authors:  Y Joy Yu; Ryan J Watts
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

6.  Kinetic analysis of novel mono- and multivalent VHH-fragments and their application for molecular imaging of brain tumours.

Authors:  U Iqbal; U Trojahn; H Albaghdadi; J Zhang; M O'Connor-McCourt; D Stanimirovic; B Tomanek; G Sutherland; A Abulrob
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

7.  Molecular imaging of glioblastoma multiforme using anti-insulin-like growth factor-binding protein-7 single-domain antibodies.

Authors:  U Iqbal; H Albaghdadi; Y Luo; M Arbabi; C Desvaux; T Veres; D Stanimirovic; A Abulrob
Journal:  Br J Cancer       Date:  2010-10-19       Impact factor: 7.640

8.  A camelid anti-PrP antibody abrogates PrP replication in prion-permissive neuroblastoma cell lines.

Authors:  Daryl Rhys Jones; William Alexander Taylor; Clive Bate; Monique David; Mourad Tayebi
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

9.  SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression.

Authors:  Lieven Huang; Lea Olive Tchouate Gainkam; Vicky Caveliers; Chris Vanhove; Marleen Keyaerts; Patrick De Baetselier; Axel Bossuyt; Hilde Revets; Tony Lahoutte
Journal:  Mol Imaging Biol       Date:  2008-02-23       Impact factor: 3.488

Review 10.  Single domain antibodies: promising experimental and therapeutic tools in infection and immunity.

Authors:  Janusz Wesolowski; Vanina Alzogaray; Jan Reyelt; Mandy Unger; Karla Juarez; Mariela Urrutia; Ana Cauerhff; Welbeck Danquah; Björn Rissiek; Felix Scheuplein; Nicole Schwarz; Sahil Adriouch; Olivier Boyer; Michel Seman; Alexei Licea; David V Serreze; Fernando A Goldbaum; Friedrich Haag; Friedrich Koch-Nolte
Journal:  Med Microbiol Immunol       Date:  2009-06-16       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.